Applicants: Jeffrey Wilusz et al. Application No.: 09/955,462 Filed: September 18, 2001

Page 3

Listing of Claims

Please amend the claims by replacing all prior versions of the claims with the following listing of claims:

- 1. (previously presented) A mammalian *in vitro* mRNA decapping system comprising:
 - a) polysome-free HeLa cell cytoplasmic extract;
 - b) a methylated cap analog; and
 - c) a cap-labeled mRNA substrate.
- 2. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 1 wherein said HeLa cell cytoplasmic extract is a HeLa S100 cell cytoplasmic extract.
- 3. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 2 wherein said HeLa cell cytoplasmic extract is prepared by dialysis of said extract containing 10% glycerol.
- 4. (cancelled)
- 5. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 2 wherein said S100 cell cytoplasmic extract comprises a 100,000 x g, 1 hour supernatant from a HeLa cell lysate.
- 6. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 1 wherein said methylated cap analog is ^{7me}GpppG or ^{7me}GTP.
- 7 8. (cancelled)
- 9. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 1 wherein said cap-labeled mRNA substrate is labeled at the alpha phosphate of the cap.

Applicants: Jeffrey Wilusz et al. Application No.: 09/955,462 Filed: September 18, 2001

Page 4

10. (currently amended) The mammalian *in vitro* mRNA decapping system of claim 1 wherein said cap-labeled mRNA substrate is labeled at the cap of said cap-labeled mRNA substrate by a label selected from the group consisting of a radioactive label, a non-radioactive isotopic label, a fluorescent moiety, a visibly-detectable moiety, a releasable substrate, [[or]] a co-factor for a chemical <u>reaction</u>, and <u>a co-factor for an enzymatic reaction</u>.

- 11. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 1 wherein said cap-labeled mRNA substrate comprises poly(A) or at least one RNA element.
- 12. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 11 wherein said RNA element is an AU-rich element.
- 13. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 11 wherein said RNA element is a pyrimidine-rich element.

14 - 16. (cancelled)

- 17. (previously presented) A kit for measuring mRNA decapping in vitro comprising:
 - a) a polysome-free HeLa cell cytoplasmic extract;
 - b) a methylated cap analog; and
 - c) cap-labeled mRNA substrate.
- 18. (cancelled)
- 19. (previously presented) The kit of claim 17 wherein said cap-labeled mRNA substrate is labeled at the alpha phosphate of the cap.

Applicants: Jeffrey Wilusz et al. Application No.: 09/955,462 Filed: September 18, 2001

Page 5

20. (currently amended) The kit of claim 17 wherein said cap-labeled mRNA substrate is labeled at the cap of said cap-labeled mRNA substrate by a label selected from the group consisting of a radioactive label, a non-radioactive isotopic label, a fluorescent moiety, a visibly-detectable moiety, a releasable substrate, [[or]] a co-factor for a chemical reaction, and a co-factor for an enzymatic reaction.

21 - 26. (cancelled)

- 27. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 1 further comprising means for sequestering proteins that bind to poly(A).
- 28. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 11 further comprising means for stimulating decapping of the cap-labeled mRNA substrate wherein the cap-labeled mRNA substrate comprises poly(A).
- 29. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 11 further comprising a cold poly(A) competitor RNA.
- 30. (previously presented) The mammalian *in vitro* mRNA decapping system of claim 12 further comprising means for reducing decapping of the cap-labeled mRNA substrate.
- 31. (currently amended) The mammalian *in vitro* mRNA decapping system of claim 12 further comprising an AU-rich element competitor RNA.
- 32. (previously presented) The kit of claim 17 wherein the cap-labeled mRNA substrate comprises poly(A).
- 33. (previously presented) The kit of claim 32 further comprising means for stimulating decapping the cap labeled mRNA substrate.

Applicants: Jeffrey Wilusz et al. Application No.: 09/955,462 Filed: September 18, 2001

Page 6

- 34. (previously presented) The kit of claim 32 further comprising a cold poly(A) competitor RNA.
- 35. (previously presented) The kit of claim 17 wherein the cap-labeled mRNA substrate comprises an RNA element.
- 36. (previously presented) The kit of claim 35 wherein the RNA element is an AU-rich element.
- 37. (currently amended) The kit of claim 36 furthering further comprising means for reducing decapping the cap-labeled mRNA substrate.
- 38. (previously presented) The kit of claim 36 further comprising an AU-rich element competitor RNA.
- 39. (previously presented) A mammalian in vitro mRNA decapping system comprising:
 - a) a polysome-free HeLa cell cytoplasmic extract;
 - b) a cap-labeled mRNA substrate; and
 - c) means for decapping the cap-labeled mRNA substrate.
- 40. (previously presented) A kit for measuring mRNA decapping in vitro comprising:
 - a) a polysome-free HeLa cell cytoplasmic extract;
 - b) a cap-labeled mRNA substrate; and
 - c) means for decapping the cap-labeled mRNA substrate.
- 41. (previously presented) The kit of claim 17 wherein the polysome-free HeLa cell cytoplasmic extract is HeLa S100 cell cytoplasmic extract.
- 42. (previously presented) The kit of claim 39 wherein the polysome-free HeLa cell cytoplasmic extract is a HeLa S100 cell cytoplasmic extract.

Applicants: Jeffrey Wilusz et al. Application No.: 09/955,462 Filed: September 18, 2001 Page 7

43. (previously presented) The kit of claim 40 wherein the polysome-free HeLa cell cytoplasmic extract is a HeLa S100 cytoplasmic extract.